Changes in Beneficial Ownership · 4
Lixte Biotechnology Holdings, Inc.
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-07-01
- Issuer
- LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- Issuer CIK
- 0001335105
- Trading symbol
- LIXT
Reporting owner 1
- Name
- Stazzone Peter
- Reporting owner CIK
- 0002083297
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- 433 PLAZA REAL, SUITE 275, BOCA RATON, FL, 33432
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-07-01 | A · Form 4 | 50,000[F1] | A | 0 | 100,000[F2] | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The reported transaction involved the Reporting Person's receipt of 50,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 50,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.↩ 1
- F2
- The total reported in Column 5 includes (i) the 50,000 newly awarded RSUs, and (ii) 50,000 RSUs, all of which have vested.↩ 1
Signature 1
- Signed
- /s/ Peter Stazzone
- Date
- 2026-07-02
Company context
We are a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. Our product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which are used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. We believe that inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. We are focusing on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity.
Recent company filings
- Regulation FD DisclosureOct 6, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesSep 30, 2026
- Financial Statements and ExhibitsSep 17, 2026
- 10-Q filingAug 14, 2026
- SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding NOMAD POWER SOLUTIONS, INC.Jul 31, 2026